Germany

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

OFEV Receives Positive Recommendation from CADTH and INESSS for the Treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)

Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OFEV

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 04, 2021

Details:

OFEV® is the first treatment available in Canada for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD), which affects patients across more than 200 rare lung disorders.

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim Collaborate to Study Nintedanib for Fibrosing ILD after COVID-19 infection

Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Ofev

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Icahn School of Medicine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 19, 2020

Details:

New study will assess the potential impact of nintedanib in patients developing pulmonary fibrosis following acute lung injury from COVID-19 infection. Research collaboration will lead to insights about pulmonary fibrosis in the growing COVID-19 patient population.